Something About Company
By the pioneering efforts of team Themis and a renewed partnership with Gedeon Richter we are on a sustainable growth trajectory. The result is
- 4 state of the art manufacturing facilities in India
- A nationwide stockist network of over 4000 stockists
- Operations in over 44 countries
Along the way, we have forged partnerships for development and marketing with many industry leaders, working symbiotically towards a healthier future. We are in business, yes, but we are also in the forefront, and this, is what motivates us to keep going to benefit patients.
Themis is well known for developing novel formulation and manufacturing APIs. The area of our focus is differentiated parenteral formulations and new drug delivery systems (NDDS) such as life saving drugs like EMAL, relatively painless injection like ETOJET, etc.
EMAL
- EMAL contains α-β Arteether, an Artemisinin derivatives indigenously developed in collaboration with CDRI.
- It is a first of its kind injectable antimalarial medicine for treatment of severe malaria which is administered ONCE daily.
- EMAL is prepared in Arachis oil and is available as 1 and 2ml ampoules (conc. 75 mg/ml)
ETOJET
- Etoject injection is the first Etoricoxib pareneteral formulation in the World.
- It is a small volume injection, available as 1 ml ampoule (Conc. 90 mg/ml) and is administered intramuscularly.
- Being less viscous, it is easily syringable.
- Because of the lower volume and less viscous nature of the formulation, it is relatively painless.
- It is protected by patent.
AQUADOL
- AQUADOL injection contains Diclofenac Sodium
- It is a small volume injection, available as 1 ml ampoule (conc. 75 mg/ml) and is administered intramuscularly.
- Being less viscous, it is easily syringable.
- Because of the lower volume and less viscous nature of the formulation, it is relatively painless
